Discover

ATNM
Actinium Pharmaceuticals, Inc.
1.10
200 x 1.08
100 x 1.12
bid
ask
+
0.02
1.85%
150 @ 04:02 PM
1.07 -0.03 (2.73%)
Ytd-19.12%
1y-26.67%
1.07
day range
1.12
0.75
52 week range
1.69
Open1.09Prev Close1.08Low1.07High1.12Mkt Cap34.59M
Vol105.76KAvg Vol139.78KEPS0.36P/E3.06Forward P/E-1.77
Beta0.15Short Ratio5.72Inst. Own30.11%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0850-d Avg1.07200-d Avg1.131yr Est5.00

ATNM News

Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)
defenseworld.net
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)

Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Confe

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actini

benzinga.com
Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacit

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development o

benzinga.com
Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2

American LLC ("NYSE American") that the Company was not in compliance with the continued lis

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
prnewswire.com
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Pr

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actini

benzinga.com
Actinium Pharmaceuticals Q2 EPS $0.89 Beats $(0.21) Estimate, Sales $35.000M

Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the a

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
defenseworld.net
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Con

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ:

Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review
defenseworld.net
Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get

benzinga.com
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutan

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
prnewswire.com
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutati

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib

benzinga.com
Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
prnewswire.com
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance t

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
prnewswire.com
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Dr

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with s

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
prnewswire.com
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optim

Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radio

benzinga.com
Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

benzinga.com
Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
prnewswire.com
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Program

Together the allowances deepen protection across two priority franchises and reinforce a patent esta

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
prnewswire.com
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June

NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actiniu

NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies
businesswire.com
NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply

BURLINGTON, Mass. & BELOIT, Wis.--(BUSINESS WIRE)--Partnership combines NorthStar's commercial-scale

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
prnewswire.com
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profil

– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its

benzinga.com
Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mecha

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, indepen

benzinga.com
Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer M

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
prnewswire.com
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, indepen

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
prnewswire.com
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225
businesswire.com
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiophar

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
prnewswire.com
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and D

New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad

benzinga.com
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overwei

Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison
defenseworld.net
Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research
businesswire.com
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 t

ATHENS, Greece & BELOIT, Wisc.--(BUSINESS WIRE)--BIOEMTECH, a developer of high-resolution PET and S

benzinga.com
Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic On

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
prnewswire.com
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"),

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premark

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 369 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  During Friday's session, 445 companies made new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Highs On Monday

  This morning 180 companies set new 52-week highs.

benzinga.com
Stocks That Hit 52-Week Highs On Tuesday

Tuesday morning saw 181 companies set new 52-week highs.

benzinga.com
81 Biggest Movers From Yesterday

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares climbed 112.5% to close at $7.80 on

benzinga.com
64 Stocks Moving In Monday's Mid-Day Session

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 218% to $11.67 after gaining

benzinga.com
31 Stocks Moving in Monday's Pre-Market Session

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 184% to $10.41 in pre-market t

benzinga.com
Stocks That Hit 52-Week Highs On Tuesday

On Tuesday, 225 companies set new 52-week highs.

benzinga.com
40 Stocks Moving in Wednesday's Pre-Market Session

Gainers Energous Corporation (NASDAQ: WATT) shares rose 126.2% to $5.00 in pre-market trading aft

benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday

benzinga.com
New 52-Week Lows For Monday Morning

New 52-Week Lows For Monday Morning

benzinga.com
Stocks Which Set New 52-Week High Yesterday, September 26th

Stocks Which Set New 52-Week High Yesterday, September 26th

benzinga.com
38 Biggest Movers From Yesterday

38 Biggest Movers From Yesterday

benzinga.com
28 Stocks Moving In Monday's Mid-Day Session

28 Stocks Moving In Monday's Mid-Day Session